Rannee naznachenie insulina glargin patsientam s sakharnym diabetom 2 tipa, prediabetom i vysokim serdechno-sosudistym riskom: rezul'taty issledovaniya ORIGIN


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article analyzes the results of the ORIGIN study (Outcome Reduction with an Initial Glargine Intervention) study, which was aimed to evaluation of the effect of achieving fasting normoglycemia by early administration of insulin glargine in patients with dysglycemia compared with standard therapy. ORIGIN study added important new data demonstrating the potential benefits of therapy with insulin glargine at an earlier stage in the development of type 2 diabetes mellitus, and has once again highlighted the infinite potentials of insulin therapy, particularly using the modern insulin analogues. Currently, in consequence of ORIGIN study, insulin glargine (Lantus ®) is the most-studied insulin analogue in the treatment of diabetes mellitus.

Texto integral

Acesso é fechado

Bibliografia

  1. ORIGIN Trial Investigators, Gerstein H., Yusuf S., Riddle M.C., Ryden L., Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155(1):26-32, 32.e1-6. Epub 2007 Nov 26.
  2. Бирюкова Е.В., Аметов А.С., Анциферов М.Б. и др. Метаболические и сердечно-сосудистые эффекты раннего назначения инсулина гларгин // Сахарный диабет 2012. № 3. С. 92-100.
  3. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 2012 Jul 26;367(4):319-28. Epub 2012 Jun 11.
  4. Pratley R.E., Matfin G. Review: Pre-diabetes: clinical relevance and therapeutic approach. Br J Diab & Vascul Dis 2007;7:120-23.
  5. Fonseca V.A. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care 2009;32(2): 151 -56.
  6. Santaguida P.L., Balion C., Hunt D., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005;(128):1-11.
  7. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010;375(9733):2215-22.
  8. Danaei G., Lawes C.M., Vander Hoorn S., et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368(9548): 1651-69.
  9. Gerstein H.C., Islam S., Anand S. , et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010;53(12):2509-17. Epub 2010 Aug 14.
  10. Saely C.H., Drexel H., Sourij H., et al. Rey role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: An angiographic Study. Atherosclerosis 2008;199(2):317-22. Epub 2008 Jan 9.
  11. Lee M., Saver J.L., Hong K.-S. Effect of pre-diabetes on future risk of stroke:meta-analysis. BMJ 2012;344:e3564. doi: 10.1136/bmj.e3564.
  12. Bartnik M., Ryden L., Ferrari R., et al. Euro Heart Survei Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004;25(21):1880-90.
  13. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1999;354(9178):602.
  14. Stumvoll M., Goldstein B.J., van Haeften T.W. Pathogenesis of type 2 diabetes. Endocr Res 2007;32(1-2):19-3 7.
  15. Weng J., Li Y., Xuet W., et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371 (9626): 1753-60.
  16. Inzucchi S.E., Bergenstal R.M., Buse J.B. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care2012;35(6): 1364-79. Epub2012 Apr 19.
  17. Hu F.B., Stampfer M.J., Solomon C.G., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001 ;161(14):1717-23.
  18. Brunner E.J., Shipley M.J., Witte D.R., et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006;29(1):26-31.
  19. The Emerging Risk Factors Collaboration. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. N Engl J Med 2011; 364(9):829-41.
  20. Lee J.H., O'Keefe J.H., Lavie C.J., et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83(3):324-32.
  21. Yokoyama M., Origasa H., Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-98.
  22. Васильева А.Д. Омега-3 полиненасыщенные жирные кислоты в профилактике и лечении атеросклероза// РМЖ2007. № 49. С. 752-7.
  23. Lepore M., Pampanelli S., Fanelli C., et al. • Длительная терапия инсулином гларгин пациентов с дисгликеми-ей характеризуется низким риском гипогликемий и незначительной прибавкой массы тела. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49( 12):2142-48.
  24. Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9(1):31-8.
  25. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49(3):442-51. Epub 2006 Feb 3.
  26. Home P.D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52(12):2499-506. Epub 2009 Sep 15.
  27. Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6):580-91.
  28. Turner R.C., Milns H., Neil H.A.W., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 1998;316(7134):823-28.
  29. Control Group, Turnbull F.M., Abraira C., Anderson R.J, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52( 11):2288-98. Epub2009 Aug 5.
  30. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol 2007; 99( 11A):12-8.
  31. Wajchenberg B.L. β-cell failure in diabetes and preservation by clinical treatment. Endocrine Rev 2007;28:187-218. Epub 2007 Mar 12.
  32. Huxley R., Ansary-Moghaddam A., Berrington D.G., et al. Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92(11):2076-83.
  33. Larsson S.C., Mantzoros C.S., Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 2007; 121 (4):856-62.
  34. The Emerging risk factors collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364(9):829-41.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2012